source
- Eli Lilly leans on cash-pay model to grow obesity drug sales in US and overseasEli Lilly has observed that patients in the United States are prepared to pay several hundred dollars each month for treatments targeting obesity. The company has focused on a cash-pay approach, s…
- Dren Bio secures $350 million to advance blood-cancer therapy toward 2027 launchDren Bio, a California biotech firm, announced it has closed a financing round that raised $350 million. The funding will be directed toward developing its lead blood‑cancer drug, with the company…